Device for treating an individual suffering from cardiac insufficiency, cardiac arrest, circulatory arrest or stroke
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10086139-B2
Publication Date
2018-10-02
Expiration Date
Abstract
The invention relates to a device for treating an individual suffering from cardiac or circulatory arrest or from a stroke, comprising a blood withdrawal device (BE) that is applied to the individual (P), an analysis unit (BA) which is directly or indirectly connected to the blood withdrawal device for detecting a blood analysis result (BAE) providing at least one characteristic of the blood, directly or indirectly connected to a blood return device (BR) that is applied to the individual (P) and is designed to deliver a substance to the individual via the return device (BR).
Core Innovation
The invention provides treatment of cardiac arrest by withdrawing blood from a patient's or an animal's circulatory system during the cardiac arrest and performing whole body reperfusion of the circulatory system. During the treatment, a reperfusion solution containing at least one substance is introduced into the circulatory system, and then modified blood is introduced. The modified blood is formed by adding the at least one substance, or at least one other substance, to the withdrawn blood so that whole body reperfusion is provided during the cardiac arrest treatment.
A central feature is automated blood analysis during the cardiac arrest treatment to determine a plurality of blood parameters representing a current condition of the patient or animal. The parameters include at least pO2, pCO2 and pH, and an output is provided representing the parameters during the treatment. During the treatment of the cardiac arrest, at least two substances are stored from which the at least one substance or the at least one other substance is selected.
Selection is performed based on the automated analysis of the determined parameters, including selecting a type and quantity of the selected at least one substance or the at least one other substance to be withdrawn from the storage. The method then introduces during the treatment first the selected at least one substance into the circulatory system and then introduces the modified blood containing the selected substance or the at least one other substance. The purpose is to lessen or prevent ischemic tissue damage during the cardiac arrest treatment.
Claims Coverage
The independent claim covers an automated, parameter-driven method for cardiac arrest treatment using extracorporeal whole body reperfusion formed by adding selected substances to withdrawn blood, with automated blood analysis determining pO2, pCO2, and pH and selection of a type and quantity of stored substances to lessen or prevent ischemic tissue damage.
Automated blood analysis during cardiac arrest treatment
Using an automated blood analysis during the treatment of the cardiac arrest to determine a plurality of parameters of the blood including at least pO2, pCO2 and pH representing a current condition of the patient or animal during the treatment and providing an output representing the parameters during the treatment.
Storing multiple substances for reperfusion modification
Storing during the treatment of the cardiac arrest at least two substances from which the at least one substance or the at least one other substance is selected for treatment of the cardiac arrest.
Parameter-based selection of substance type and quantity
Selecting, based on the automated analysis of the determined parameters, a type and quantity of the at least one substance or the at least one other substance to be withdrawn from the storage.
Whole body reperfusion using modified withdrawn blood
Introducing during the treatment of the cardiac arrest first the selected at least one substance into the circulatory system and then introducing the modified blood containing the at least one substance or the at least one other substance into the circulatory system to provide the whole body reperfusion of the circulatory system during the treatment of the cardiac arrest, wherein lessens or prevents ischemic tissue damage during the treatment of the cardiac arrest.
Overall, the claim ties together automated blood parameter measurement (including pO2, pCO2, and pH), storage of at least two selectable substances, selecting a type and quantity based on the analysis, and delivering whole body reperfusion by introducing both a reperfusion solution substance and subsequent modified blood formed from withdrawn blood plus the selected substance, to lessen or prevent ischemic tissue damage.
Stated Advantages
Lessens or prevents ischemic tissue damage during the treatment of the cardiac arrest.
Documented Applications
Treatment of cardiac arrest by withdrawing blood during cardiac arrest and providing whole body reperfusion during the treatment using modified blood.
Treatment context includes cardiac arrest with cardiac arrest occurring before the start of treatment.
Interested in licensing this patent?